Valuing Early-Stage Life Sciences Companies

The Why, the How, and the Impact 

Ron Melling, Tom Shoemaker, Michael Taglieri
3/18/2026

This article was originally published March 10, 2026, in MedCity News.

Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.

Read the full article on MedCity News

Professionals discuss data on a laptop, representing valuation and capital planning for early-stage life sciences companies.
Read the article
Guidance for life sciences
Get help navigating risk, compliance, supply chain, and growth opportunities.

Contact us

Ron-Melling-225
Ron Melling
Partner, Audit & Assurance, Crowe LLP
Partner, Crowe Advisory LLC
Tom Shoemaker at Crowe LLP.
Tom Shoemaker
Partner, Audit & Assurance, Crowe LLP
Partner, Crowe Advisory LLC
Michael Taglieri
Michael Taglieri
Managing Director, Advisory,
Crowe Advisory LLC

Related insights

loading gif
Two business professionals reviewing information on a laptop and tablet during a collaborative discussion.
When Life Sciences Companies Need Compliance Expertise
Explore when life sciences companies need compliance expertise to manage regulatory risk, support growth, and build the right capabilities.
Professionals engaged in a presentation during a business meeting.
Top Risks in Internal Audit for 2027
In this webinar recording, Crowe specialists explore risks for internal audit in 2027 and share ideas to strengthen governance and compliance.
Life sciences researchers conduct laboratory testing, highlighting operational risks relevant to internal audit planning.
Top Risk Areas for Internal Audit Planning: Life Sciences
Crowe specialists review 2027 internal audit planning for life sciences organizations, including for cybersecurity, data privacy, AI, and compliance.
Two business professionals reviewing information on a laptop and tablet during a collaborative discussion.
When Life Sciences Companies Need Compliance Expertise
Explore when life sciences companies need compliance expertise to manage regulatory risk, support growth, and build the right capabilities.
Professionals engaged in a presentation during a business meeting.
Top Risks in Internal Audit for 2027
In this webinar recording, Crowe specialists explore risks for internal audit in 2027 and share ideas to strengthen governance and compliance.
Life sciences researchers conduct laboratory testing, highlighting operational risks relevant to internal audit planning.
Top Risk Areas for Internal Audit Planning: Life Sciences
Crowe specialists review 2027 internal audit planning for life sciences organizations, including for cybersecurity, data privacy, AI, and compliance.